Decision Support

Agendia Inc. is a molecular diagnostics company specializing in genomic testing for early-stage breast cancer. The company develops and provides MammaPrint and BluePrint, two FDA-cleared genomic profiling tests that analyze tumor biology to assess recurrence risk and determine molecular subtype. MammaPrint is a 70-gene recurrence risk assay for HR+/HER2− early-stage breast cancer patients, while BluePrint is a molecular subtyping test that identifies the underlying genomic drivers of tumor growth. Results are delivered within 6 business days from a single tissue sample. These tests enable oncologists to personalize treatment decisions and reduce both under- and over-treatment. Agendia's assays are validated by multiple landmark clinical studies and recognized by major treatment guidelines including NCCN (National Comprehensive Cancer Network). The company serves leading physicians and institutions globally and maintains CLIA, CAP, and ISO certifications for laboratory operations. Agendia operates a CLIA-certified laboratory and provides test ordering through multiple physician portals. The company markets its services to oncology practices, cancer centers, and health systems in the Americas, Europe, and internationally.

Bunkerhill Health is an AI-enabled healthcare platform that facilitates the development, validation, regulatory approval, and deployment of artificial intelligence algorithms in clinical settings. Founded in 2019 and based in San Francisco, the company connects academic medical researchers with healthcare systems to accelerate the translation of AI innovations from research to clinical practice. The platform leverages generative AI and large language/vision models to provide clinical reasoning and automated action across the entire health system. It integrates electronic health record (EHR) data and employs FDA-cleared algorithms to analyze patient information, identify clinical risks, group patients for targeted interventions, and automate complex workflows including prior authorization, clinical trial matching, preventive care coordination, radiology finding follow-up, cancer registry submission, and care documentation. Key applications span cardiovascular care, cancer screening, critical care, preventive care, and operational efficiency. Bunkerhill's Carebricks platform enables healthcare systems to design and deploy custom AI-powered workflows for any clinical or operational domain without requiring extensive development cycles. The company has established partnerships with leading health systems including UCSF, Mayo Clinic, Georgetown/MedStar, and UTMB Health, and is supported by prominent investors including Sequoia Capital, Optum Ventures, Y Combinator, and others.

Great Lakes NeuroTechnologies (GLNT) is a biomedical technology company specializing in physiological monitoring systems and patient-centered diagnostic platforms for movement disorders, telemedicine, and in-home health monitoring. Founded in 2010 and based in Independence, Ohio, GLNT designs, manufactures, and distributes wireless and web-based bioinstrumentation products for clinical, research, and educational applications. The company's primary offerings include the Kinesia line of wearable systems for real-time motor symptom assessment in Parkinson's disease and essential tremor, and the BioRadio wireless data acquisition platform for research and education. GLNT holds over 50 patents in neurological and movement disorder monitoring, with recent innovations in AI-driven therapy adjustment and remote deep brain stimulation (DBS) programming. The company serves physicians, medical technicians, healthcare practitioners, researchers, universities, and hospitals, addressing clinical needs in remote patient monitoring, clinical trial management, and therapy optimization.

Ubiosis Health develops UBi, an AI-driven healthcare agent and autonomous nursing platform purpose-built for inflammatory bowel disease (IBD) management. UBi bridges gaps between clinic visits through continuous at-home biomarker monitoring (fecal calprotectin, weight, heart-rate variability), real-time EMR data streaming, natural-language patient engagement via mobile app, and automated clinical workflows including prior authorizations and lab ordering. The platform implements STRIDE-II treat-to-target guidelines at scale, enabling early flare detection and proactive intervention before symptoms escalate. Designed for seamless integration into existing gastroenterology practice workflows without requiring new staff or system installations, UBi delivers clinical outcomes (5× increase in sustained remission rates, 81% reduction in adverse events per CALM trial data) while generating new reimbursable revenue through remote patient monitoring and chronic care management CPT codes. The platform has conducted over 1,200+ patient check-ins weekly and is partnered with leading academic medical centers and health systems.

Tempus AI is a precision medicine platform that leverages artificial intelligence and multimodal data analytics to accelerate clinical decision-making and drug development. The company provides healthcare providers and researchers with AI-enabled diagnostic and research tools, including genomic sequencing (xT and xR IVD platforms), algorithmic models (such as PurIST for therapy selection), and clinical trial matching capabilities. Tempus integrates extensive molecular profiling with real-world clinical data to identify personalized therapeutic opportunities, support guideline-concordant care, and enable earlier disease diagnosis across oncology and other therapeutic areas. The platform serves academic medical centers, oncologists, pharmaceutical companies, and biotech firms, supporting precision medicine workflows from diagnosis through treatment optimization.

Welldoc is a digital health platform company specializing in AI-driven chronic disease management, with a focus on diabetes, hypertension, heart failure, obesity, and behavioral health. Founded in 2005 by an endocrinologist, Welldoc delivers clinically-validated, evidence-based solutions that integrate personalized, real-time insights into patient workflows. The flagship product, BlueStar® (FDA-cleared prescription digital therapeutic), provides automated patient coaching and real-time guidance for adults with type 2 diabetes. Welldoc's platform enables "care anywhere" delivery models for health plans, healthcare systems, and employers, integrating disparate health data into actionable clinical insights across the cardiometabolic spectrum. The company collaborates with major partners including Abbott, CVS Health, Eli Lilly, Dexcom, and others, leveraging data science and behavioral algorithms to improve medication adherence, lifestyle change, and self-management outcomes.

Mint Medical GmbH is a Heidelberg-based medical imaging software company specializing in advanced analytics and structured reporting solutions for diagnostic radiology, clinical trials, and imaging biomarker research. The company's flagship product, mint Lesion, is a computer-assisted diagnostic platform that converts CT, MRI, and PET imaging data into standardized, actionable insights. The software provides AI-augmented guided structured reporting, implements dynamic response criteria (RECIST 1.1, iRECIST, CHESON, TNM, PI-RADS, RANO) with automated compliance checks, supports collaborative multi-reader workflows, and enables advanced analytics including volumetrics, radiomics, and tumor growth rate analysis. mint Lesion generates FHIR-compliant, high-quality structured datasets suitable for clinical routine oncology departments, Phase I-III clinical trials, pharmaceutical companies, CROs, and real-world data research. The platform integrates with existing PACS and RIS systems and is now part of the Brainlab Snke OS ecosystem following acquisition in 2021.

OraQ AI is a Calgary-based dental technology company that develops OraQ™, an FDA and Health Canada-approved AI-powered clinical decision support system for dental practices. The platform uses machine learning to standardize comprehensive patient assessments and generate precision treatment recommendations across hygiene, restorative, and specialty procedures including orthodontics, obstructive sleep apnea, and temporomandibular disorder management. OraQ™ integrates with leading practice management systems (ClearDent, Dentrix, Tracker, OpenDental) to analyze patient data and risk profiles, enabling early intervention and personalized care planning. The system is designed for dental practices of all sizes—from solo practitioners to multi-practice and DSO organizations—helping clinicians uncover high-value treatment opportunities and improve patient outcomes. Clinical teams report up to 70% case acceptance rates and $250–$330 additional treatment recommendations per exam.

IRM Inc. is a healthcare software solutions provider specializing in cloud-based enterprise data management and clinical decision support systems. The company develops PACS and imaging informatics platforms designed to streamline hospital and clinic workflows while enabling secure access to medical imaging data and AI-driven analytics. IRM's offerings focus on clinical efficiency, data orchestration, and collaborative research capabilities, allowing healthcare organizations to eliminate traditional hardware infrastructure while maintaining robust data security and compliance standards.

Asuragen is a molecular diagnostics company specializing in genetic carrier screening and precision oncology testing. Founded in 2006 and acquired by Bio-Techne Corporation in 2021, the company develops advanced diagnostic solutions utilizing proprietary chemistries and miRNA-based technologies. Their product portfolio includes genetic testing kits for inherited disorders (Fragile X, CFTR, SMN1/2, HTT), precision oncology solutions for chronic myeloid leukemia (CML) and solid tumor monitoring, custom molecular quality controls, and armored RNA controls. The AmplideX product line encompasses PCR/CE-based assays optimized for clinical laboratories. Asuragen operates a GMP-compliant manufacturing facility and CLIA-certified laboratory, serving clinical diagnostics and research applications across oncology, genetic disorders, and carrier screening markets. The company maintains strategic partnerships and distributes products across North America and EMEA regions.

Siemens Healthineers AG is a global leader in medical technology specializing in diagnostic imaging, laboratory diagnostics, precision therapy, and advanced healthcare solutions. Founded in 1847 and spun off as an independent entity in 2015, the company employs approximately 74,000 people worldwide and invests over €1 billion annually in research and development. The company's portfolio encompasses advanced imaging technologies including PET-CT scanners, MRI systems, and wireless ultrasound transducers, alongside laboratory diagnostics platforms conducting over 9 billion tests annually. Siemens Healthineers is particularly renowned for precision therapy innovations in oncology, featuring image-guided treatments and radiation therapy solutions. The company operates in more than 70 countries, with solutions trusted by 90% of leading hospitals globally. Its AI-driven diagnostic software and digital tools optimize clinical workflows and support early disease detection, particularly for lung and prostate cancer screening. The company maintains strategic partnerships with major healthcare providers and research institutions to enhance innovation and patient outcomes.

TytoCare is an AI-powered remote physical examination platform that enables clinicians to conduct comprehensive diagnostic exams from any location—home or community site. The company's Smart Clinic solutions include FDA-cleared hardware (digital stethoscopes, examination cameras) and advanced diagnostic software that replicates in-person clinical assessments for heart, lungs, throat, ears, skin, abdomen, and vital signs (temperature, heart rate). TytoCare serves 240+ healthcare organizations, 1.6M+ patients, and 40K+ providers globally, with deep integrations across health systems, health plans, and Medicaid programs. The platform features FDA-cleared AI algorithms for detection of pulmonary abnormalities (wheeze, rhonchi, crackles) and clinical decision support. Two primary offerings: Home Smart Clinic for patient self-exams with remote clinician supervision, and Pro Smart Clinic for field-based clinician-conducted exams. Clinical evidence demonstrates 6X higher utilization versus traditional telehealth, 98% remote resolution rate, 8.5% total cost-of-care reduction, and 83 NPS score. Trusted by Corewell Health, Sanford Health, Clalit, Elevance, Presbyterian, and major U.S. health systems.

SpeeDx Pty Ltd is an Australian molecular diagnostics company specializing in multiplex PCR assays and proprietary technologies for detecting viral and bacterial infections, including antibiotic resistance markers. Founded in 2009 and headquartered in Sydney, the company develops PlexZyme®, PlexPrime®, and PlexPlus® multiplexing technologies that enable simultaneous detection of multiple diagnostic targets with high sensitivity and specificity. SpeeDx serves reference laboratories, diagnostic companies, instrument manufacturers, pharma, and biotech organizations globally. The company offers three core product lines: multiplexed IVD products for clinical diagnostics (sexually transmitted infections, respiratory, enteric panels), targeted research assays for infectious disease research, and custom development solutions. Beyond products, SpeeDx provides comprehensive partnering services including technology licensing, bespoke assay development, regulatory strategy, and manufacturing scale-up support. The company's multiplexing platform can achieve up to 12+ targets per well with unparalleled specificity for mutation differentiation, significantly reducing testing costs and time-to-result while improving laboratory efficiency across major molecular platforms.

Elvo is a clinician-directed, voice-guided AI support system designed to reinforce evidence-based speech-language pathology and cognitive rehabilitation interventions in home and care environments. The platform operationalizes well-documented therapeutic principles including structured repetition, hierarchical cueing, external pacing, and strategy carryover to address gaps in therapy frequency and patient compliance between skilled visits. Elvo supports diverse clinical applications including language and communication (word retrieval, naming, sentence formulation), voice and motor speech (metronome pacing, articulation drills, rate control), swallowing adjacent practice, cognition and cognitive communication (problem-solving, attention tasks, memory), and functional conversation training. The system generates quantitative metrics (response latency, utterance length, elaboration rate) across >1000 documented therapy sessions and has demonstrated clinically meaningful outcomes in users with aphasia, Parkinson's disease, mild cognitive impairment, and mixed cognitive-communication disorders. HIPAA-compliant with Zero Data Retention (ZDR) for AI processing and BAAs with all PHI-handling vendors. Designed as a complement to—not replacement for—clinical therapy.

DiaPharma Group, Inc. manufactures specialty research and clinical assay kits, reagents, and hemostasis analyzers for bleeding/clotting disorders, thrombosis, liver disease, drug-induced organ injury, and anti-cancer drug development. Founded in 1997, the company employs scientists with expertise in hemostasis, coagulation testing, platelet function analysis, fibrosis biomarkers, and NETosis research. DiaPharma offers chromogenic substrates, ADAMTS13 assays, Factor X testing, and mechanistic biomarkers for MASH, alcoholic liver disease (ALD), and drug-induced liver injury (DILI). The company provides personalized scientific support and customer service to clinical laboratories, research institutions, and pharmaceutical development teams.

Vasc-Alert LLC is an FDA-approved AI-powered vascular access surveillance platform designed specifically for dialysis centers. The company provides validated, data-driven decision-support software that monitors arteriovenous (AV) fistulas and grafts for early stenosis detection and access complications without requiring additional patient testing or interrupting treatment sessions. The system analyzes clinical data already present in patient records to generate weekly risk assessments and trending reports, enabling nephrologists and vascular access coordinators to identify troubled accesses proactively and prevent catheter conversions. Vasc-Alert helps dialysis providers reduce CMS catheter penalties, improve patient outcomes through early intervention protocols, and optimize clinical metrics such as treatment adequacy. The platform includes patient education tools and integrates with existing dialysis center workflows to support value-based care delivery and access longevity improvement.

Healthcare Outcomes Performance Company (HOPCo) is the leading orthopedic value-based care organization in the United States, specializing in musculoskeletal (MSK) health outcomes management, service line optimization, and practice management. Based in Phoenix, Arizona, HOPCo operates a comprehensive platform managing the entire continuum of MSK care across orthopedics, spine, pain management, and rehabilitation. The company serves three primary customer segments: MSK practices seeking growth acceleration and sustainable models, health systems pursuing service line optimization and market transformation, and payors implementing population health programs. HOPCo's differentiated platform combines physician-led value-based care programs, advanced medical economics and analytics, clinically integrated networks (including the only URAC-accredited MSK network nationally), and digital patient engagement tools. The company has demonstrated impact in improving clinical outcomes, reducing total cost of MSK care, and enhancing patient access. HOPCo operates across 30+ states with established partnerships among health systems, independent practices, and major payors including Humana.

Harmony Healthcare IT (HHIT) is a healthcare IT data management firm based in South Bend, Indiana, specializing in enterprise-scale data lifecycle solutions for healthcare organizations. Founded in 2006, the company serves 550+ healthcare clients and manages billions of records across 700+ software brands. HHIT provides end-to-end data services including extraction, migration, archiving, integration, and analytics with a focus on security, compliance, and operational efficiency. The company's HealthData Platform™ offers unified data management capabilities, including legacy data archiving with hot, warm, and cold storage options. HHIT recently launched ClearWay, an AI-powered platform automating clinical abstraction and submission. The company holds HITRUST certification and implements 560+ security controls to ensure HIPAA compliance. With proven 90+ customer loyalty indicators and virtual project delivery capabilities, HHIT delivers affordable, scalable solutions that help healthcare organizations optimize operations while protecting patient data.

Cloudphysician is an AI-driven healthcare technology company providing AI-powered Smart-ICU solutions and virtual critical care services. Founded in 2017 by critical care physicians, the company operates the proprietary RADAR platform—an ambient intelligence system integrating high-definition video, computer vision, AI analytics, and electronic medical record data to enable 24/7 remote ICU monitoring and clinical decision support. The platform detects and prevents adverse events including inpatient falls, pressure ulcers, central line infections, and catheter-associated UTIs, reducing hospital-acquired complications and associated costs. Cloudphysician has deployed solutions across 280+ hospitals managing 2,000+ ICU beds across 22 Indian states, serving 130,000+ patients. The company offers disease-specific AI agents, real-time video analysis, virtual nursing capabilities, and Smart-ICU in a Box solutions optimized for both urban and rural healthcare settings. Its hardware-agnostic architecture integrates seamlessly with existing hospital infrastructure (monitors, cameras, tablets) without requiring device upgrades. The platform operates securely on-premise or in cloud environments with full HIPAA, SOC 2, and ISO 27001 compliance, ensuring patient data remains within hospital environments with no external data transfer.

Pentapharm AG is a Swiss manufacturer of active pharmaceutical ingredients (APIs), diagnostic reagents, and biochemical products founded in 1948 and headquartered in Aesch, Basel-Landschaft. Specializing in hemostasis, coagulation, and anticoagulation therapies, the company supplies the pharmaceutical and diagnostic industries with naturally derived APIs including Aprotinin, Batroxobin, and Haemocoagulase—all supported by Drug Master Files (DMFs) and CEP certificates. The company manufactures standardized biochemicals for research, quality control, and analytical applications; highly purified snake venom enzymes for plasma coagulation and fibrinolysis modulation; proteinase inhibitors for proteolytic control; and synthetic peptide substrates (chromogenic, fluorogenic, amperogenic) for diagnostic assay development and proteinase activity monitoring. Pentapharm also develops and produces in-vitro diagnostic (IVD) reagent kits and research-use-only (RUO) kits for coagulation and fibrinolysis analysis. All manufacturing operates under GMP standards with strong emphasis on regulatory compliance, quality assurance, and accelerated time-to-market for partner pharmaceutical and diagnostics companies.

Cambridge Cognition is a neuroscience technology company specializing in digital cognitive assessment platforms for central nervous system (CNS) clinical trials. With over 30 years of scientific validation and expertise, the company provides an end-to-end solution for pharmaceutical companies, contract research organizations, and academic institutions. Core offerings include CANTAB® touchscreen cognitive assessments, voice analysis for verbal cognitive testing, electronic questionnaires and scales, high-frequency testing capabilities, decentralized clinical trial management, and automated quality assurance for clinical scales. The platform supports remote patient monitoring and decentralized trial recruitment, enabling drug developers to conduct cognitive efficacy and safety assessments in clinical or home settings. Cambridge Cognition's assessments have been validated across 3,000+ peer-reviewed publications and 250+ disease indications, including Alzheimer's disease, ADHD, depression, Parkinson's disease, multiple sclerosis, and schizophrenia. The company serves as a trusted partner for detecting subtle cognitive changes and generating objective biomarkers to accelerate brain health research and drug development timelines.

SmartCardia is a Swiss health technology company offering a comprehensive cardiology and remote patient monitoring solution. The core product is a wearable 7-lead ECG patch—cable-free, waterproof, and reusable—capable of 7–14 day continuous monitoring. All ECG leads and vital signs (respiration, SpO2, activity) stream in near real-time to a cloud-based SaaS platform powered by SmartNeuralNet, a proprietary machine learning engine trained on millions of cardiologist-annotated ECG segments. The platform delivers automated arrhythmia detection, patient deterioration prediction, and full-disclosure ECG analysis, enabling clinicians to transition patients seamlessly between Holter, Extended Holter, Mobile Cardiac Telemetry, and Remote Patient Monitoring without additional visits. FDA-cleared and CE Class IIa approved, SmartCardia serves 100+ hospitals globally with live 24/7 monitoring, immediate clinical notifications, and comprehensive reporting. The solution reduces manual analysis time, lowers staffing costs, and supports continuous care from cardiac screening through post-discharge and long-term monitoring.

Neurolief is a neuromodulation medical device company specializing in non-invasive, FDA-approved brain stimulation systems for treating major depressive disorder (MDD), migraines, stress, and sleep disorders. The company's flagship product, Proliv™Rx, delivers combined occipital and trigeminal afferent stimulation (eCOT-AS) as a home-based, physician-directed adjunctive therapy for adults with treatment-resistant depression who have failed antidepressant medications. The system enables 8-16 week treatment programs delivered entirely at home with continuous clinician oversight and symptom tracking, eliminating the need for specialized clinic infrastructure, staffing burden, or geographic limitations. Clinical evidence demonstrates 87% of patients show improvement in depression severity with 96% treatment adherence. Proliv™Rx is FDA-approved in the USA, CE-marked in Europe, and PMDA-approved in Japan. The company also offers wearable neuromodulation devices including Relivion MG for acute and preventive migraine relief. All solutions leverage intelligent companion apps enabling remote patient monitoring and personalized treatment management outside traditional clinical settings.

BrainScope is a commercial-stage medical neurotechnology company specializing in AI-powered EEG-based diagnostic solutions for brain health. Founded in 2006 and based in Rockville, Maryland, BrainScope has developed a proprietary platform that applies machine learning and computational neuroscience to transform brain electrical activity (EEG) into objective clinical biomarkers. The company created the first FDA-cleared AI/Machine Learning medical device in neurology and holds a portfolio of 83 issued patents. BrainScope's primary offering is a hand-held, point-of-care device for assessing mild traumatic brain injuries (mTBI), structural brain bleeds, and concussions in under 20 minutes. The technology has demonstrated ~50% reduction in unnecessary head CT scans and substantial reductions in emergency department patient length of stay. Beyond head injury assessment, BrainScope is developing novel biomarkers for stroke detection, early Alzheimer's detection (with dementia risk prediction up to 7 years before initial diagnosis), and other CNS indications. The company serves acute care settings, hospitals, emergency departments, and pharmaceutical/drug development partners.

Cogstate Ltd is a neuroscience solutions company specializing in digital cognitive assessment platforms for clinical research and healthcare. Founded in 1999, the company provides validated, computer-based cognitive testing tools designed to measure brain health across connected devices. Cogstate's offerings include digital cognitive assessments, remote assessment capabilities for decentralized clinical trials, endpoint data quality services (rater training and monitoring), and healthcare cognitive screening solutions for clinical care settings. The company supports biopharmaceutical companies and academic institutions in clinical trials across 100+ indications, serving researchers worldwide. With 25 years of expertise, Cogstate has administered over 2 million digital tests and completed 35,800+ rater trainings. The platform is culture-neutral and optimized for precision in pharmaceutical studies, early-phase safety assessments, and cognitive impairment evaluation across conditions including Alzheimer's disease, Parkinson's disease, schizophrenia, and concussion. Cogstate's solutions are applied in neurology, sports medicine, and pharmaceutical development.

Nox Medical is a specialized sleep diagnostics company founded in 2006 and headquartered in Reykjavík, Iceland. The company designs and manufactures portable polysomnography (PSG) systems and home sleep testing (HST) devices for sleep medicine practitioners globally. Nox Medical's flagship products include the Nox A1 PSG System—a full portable polysomnography platform for in-lab and ambulatory sleep studies—and the Nox T3s HST Device, a next-generation home sleep testing system. Both platforms incorporate AI-assisted scoring and data management capabilities to enhance diagnostic accuracy and simplify workflow. The company's technologies are deployed across 50 countries by sleep medicine centers, hospitals, and research institutions to diagnose sleep disorders including obstructive sleep apnea. Nox Medical emphasizes user-friendly design, patient comfort, and scalable solutions that expand access to sleep diagnostics across diverse patient populations.

InBios International, Inc. is a privately-held biotechnology company specializing in the design, development, and manufacture of immunodiagnostic devices for infectious diseases and biothreats. Founded in 1996 and headquartered in Seattle, Washington, the company operates a state-of-the-art GMP-compliant, FDA-registered manufacturing facility certified to ISO 13485:2016. InBios maintains a portfolio of over 25 FDA-cleared diagnostic products and extensive life science reagent catalogs. Core offerings include ELISA kits, rapid point-of-care tests, and contract manufacturing services for emerging infectious disease diagnostics. The company delivers immunoassays targeting dengue, West Nile virus, Zika, Chagas disease, leishmaniasis, COVID-19, influenza, and biothreats such as anthrax and melioidosis. InBios provides comprehensive assay development, regulatory affairs support, and contract manufacturing capabilities to clinical laboratories, public health agencies, research institutions, and OEM partners globally. The company is recognized for rapid response to emerging disease threats while maintaining rigorous quality standards and cost-effective solutions for the global diagnostic market.

PeriGen is a perinatal healthcare software company with over 27 years of experience developing solutions for labor and delivery management. The company specializes in maternal-fetal surveillance and early warning systems designed to prevent complications during childbirth. PeriGen's flagship platform, PeriWatch, includes advanced fetal heart rate pattern analysis, automated risk detection, and clinical decision support tools. The company's solutions integrate with electronic fetal monitoring systems and electronic medical records to provide real-time data analysis and clinician alerts. PeriWatch Vigilance uses FDA-cleared machine learning algorithms to continuously interpret fetal heart rate patterns and detect labor progress anomalies. Additional offerings include centralized monitoring command centers, mobile applications for clinician access, quality reporting dashboards, and automated safety threshold notifications. PeriGen serves over 500 hospitals across the United States and Canada, supporting approximately 750,000 births annually. The company emphasizes responsible AI implementation that complements rather than replaces clinical expertise, with published outcomes data demonstrating impact on maternal and fetal safety.

Epitel, Inc. is a digital health company based in Salt Lake City, Utah, specializing in innovative wearable EEG monitoring technology for brain health. Founded in 2008, Epitel developed the REMI™ Remote EEG Monitoring System, an FDA-cleared (2021) wireless, wearable sensor platform designed for seizure detection and electrographic monitoring in both hospital and ambulatory settings. The system features single-channel, high-fidelity EEG recordings with rapid setup (minutes), wireless operation enabling patient mobility, and integration with standard EEG review platforms like Persyst™ Mobile for remote clinician review. REMI Vigilenz™ AI for Event Detection augments clinical review by automatically identifying potential electrographic seizure activity with confidence scoring. The platform is clinically validated, reimbursable under existing codes, and suitable for adult and pediatric patients (1+ years for monitoring; 6+ years for AI analysis). Epitel's technology addresses critical care, emergency department, and outpatient epilepsy monitoring needs. The company has secured over $20 million in funding and brings extensive expertise in medical device development, neural engineering, and regulatory affairs.

Videra Health is an AI-powered behavioral health technology platform that automates clinical documentation, remote patient monitoring, and clinical decision support through multimodal analysis of video, audio, and text data. Founded in 2019 and based in Orem, Utah, the company serves 300+ behavioral health facilities with 1M+ patient interactions. The platform features automated patient intake, AI-generated clinical summaries (Sidekick Notes), real-time emotional and risk analysis, and 24/7 patient engagement across multiple channels (video, voice, chat, SMS). Key capabilities include suicide risk detection, tardive dyskinesia screening, and group therapy documentation. Videra's system delivers measurable operational outcomes: 2+ clinician hours reclaimed daily, 85% faster patient engagement, and 64% reduction in crisis interventions. HIPAA and SOC 2 Type II compliant, FDA-registered, and designed specifically for behavioral health workflows in value-based care models.

ARUP Laboratories is a national, academic, nonprofit reference laboratory established in 1984 as part of the University of Utah's Department of Pathology. Operating 65 highly automated laboratory facilities with 4,300 employees, ARUP serves healthcare providers nationwide with over 3,000 diagnostic tests. The laboratory maintains a two-story freezer capable of storing 2.3 million specimens and provides industry-leading turnaround times. ARUP's test menu encompasses genetics, molecular oncology, pediatrics, neurology, hematopathology, and infectious disease testing. Beyond core laboratory services, ARUP offers comprehensive consulting through its Healthcare Advisory Services division, addressing laboratory stewardship, operations optimization, outreach planning, and data analytics. The company maintains a robust research and innovation program through its Institute for Research and Innovation in Diagnostic and Precision Medicine, supporting clinical trials, pharmaceutical companion diagnostics, and academic research initiatives. ARUP provides ARUP Consult®, a clinical decision support resource featuring testing algorithms and expert insights, alongside continuing education for laboratory professionals. CAP-, CLIA-, and ISO 15189-accredited, ARUP serves academic medical centers, children's hospitals, government facilities, and healthcare systems across the U.S.

CEIBA Health Technologies is an AI-powered healthcare technology platform specializing in virtual clinical care and medical device connectivity solutions. The company delivers an integrated Enterprise Suite with four core capabilities: (1) IoMT Interoperability—featuring a plug-and-play IoMT Box with 1,000+ pre-installed device drivers supporting 20+ EHR integrations; (2) Continuous Monitoring—delivering real-time telemetry dashboards for patient monitors, ventilators, infusion pumps, blood gas analyzers, and EEG machines across ICU, med-surge, LTACH, and SNF settings; (3) Decision Support & Workflow—providing actionable clinical insights and operational dashboards; and (4) Virtual Clinical Care—a telehealth platform enabling multi-specialty consultations, remote rounding, and acute care at home. CEIBA's protocol-agnostic architecture supports HL7, FHIR, JSON, and XML with enterprise-grade security, encrypted data transfer, and full mobile functionality. The platform is designed for rapid deployment (days vs. months) and serves hospitals and health systems in the US and internationally.

Cytovale is a medical diagnostics company headquartered in South San Francisco, specializing in rapid sepsis detection and immune-mediated disease diagnostics. The company's flagship product, IntelliSep®, is an FDA-cleared in vitro diagnostic test that delivers sepsis risk stratification results in approximately 8 minutes from a standard blood draw. IntelliSep analyzes the biomechanical properties of white blood cells to assess immune activation and predict the probability of sepsis with organ dysfunction within 3 days of testing. Designed for emergency departments, IntelliSep enables rapid patient triage, reduces unnecessary antibiotic use and blood cultures, shortens length of stay, and improves operational throughput. The company's deformability cytometry platform represents a significant advancement in rapid infectious disease diagnostics, addressing a critical gap in sepsis detection where earlier treatment initiation directly correlates with improved patient survival outcomes.

ASCEND Cardiovascular is a specialized cardiovascular IT solutions provider headquartered in Springfield, Illinois. Founded in 1995, the company develops enterprise-grade structured reporting and workflow software designed exclusively for cardiology departments and health systems. The ASCEND CV portfolio delivers multimodality structured reporting capabilities that integrate diagnostic, procedural, and reporting workflows into a unified cardiovascular ecosystem. Core offerings include ASCEND CV (multimodality reporting software), ASCEND InView (zero-footprint DICOM viewer), Gen3Echo (AI-driven echocardiography reporting), ASCEND Analytics (open-schema data warehouse), and Catalyst LIVE (telepresence collaboration platform). The company provides vendor-agnostic solutions with device interfaces, clinical decision support, and implementation services. ASCEND serves leading North American health systems and hospitals, with specialized solutions for pediatric cardiology, congenital heart disease, and non-invasive cardiac imaging. The platform integrates seamlessly with major EHR/HIS systems and medical device manufacturers including Epic, Cerner, GE Healthcare, Philips, and AGFA Healthcare.

Theranica Bio-Electronics is a digital therapeutics company specializing in neuromodulation devices for neurological pain management, particularly migraine treatment. The company develops prescription wearable devices that deliver remote electrical neuromodulation (REN) to peripheral nerves, leveraging the Conditioned Pain Modulation (CPM) mechanism—an endogenous analgesic pathway that inhibits pain through non-invasive peripheral stimulation. Their flagship product, Nerivio, is a clinically proven, drug-free wearable that stimulates upper arm peripheral nerves to trigger CPM, enabling patients to manage migraine pain without pharmaceutical intervention. The technology addresses dysfunctional pain processing in neurological conditions by delivering targeted peripheral stimuli that activate pain-inhibiting neurotransmitter release in the brain stem. Theranica's approach combines clinical rigor with accessibility, positioning digital therapeutics as a safe, affordable alternative to traditional pain management.

ChatRx is an FDA-approved, AI-powered asynchronous telemedicine platform specializing in diagnosis and treatment of 39 common acute infections. The platform combines proprietary AI-assisted symptom assessment with physician review and oversight to deliver care 24/7 without requiring video appointments or scheduled consultations. Available in Indiana, Illinois, and Michigan, ChatRx addresses healthcare access gaps for uninsured patients, rural communities, shift workers, and others facing barriers to traditional urgent care. The service operates on a flat-fee model ($25 per consultation, $10 for work/school notes) and provides treatment plans with prescriptions when medically appropriate. The platform achieves >90% diagnostic accuracy and includes integration with pharmacy networks for prescription delivery.

Implicity is a cloud-based digital MedTech software company specializing in AI-driven remote cardiac monitoring and research solutions for healthcare providers. Founded in 2016, the platform centralizes and standardizes cardiac implantable electronic device (CIED) data from multiple manufacturers (Abbott, Biotronik, Boston Scientific, Medtronic, Microport) into a single unified dashboard. The FDA-cleared, CE-marked platform employs patented AI algorithms to filter clinical alerts, reduce false positives by up to 79%, and prioritize clinically relevant events for faster clinical decision-making. Key solutions include vendor-neutral CIED remote monitoring, ILR ECG Analyzer (for Medtronic implantable loop recorders), AF Alert Management, SignalHF Predictive AI for heart failure risk stratification, and advanced research tools for real-time clinical data collection. The platform demonstrates proven clinical impact: 26% reduction in mortality, 4% reduction in hospitalization length, and 85% reduction in unnecessary atrial fibrillation alerts. Implicity serves over 100,000 patients across more than 250 medical facilities in the United States and Europe, with offices in Cambridge, Massachusetts, and Paris, France.

AlgoDx AB is a Stockholm-based healthcare AI company founded in 2018 that develops clinically validated machine learning algorithms for sepsis management and clinical decision support in intensive care settings. The platform integrates with electronic health records (EHR) to analyze patient data in real time, flagging rising sepsis risk and automating CMS SEP-1 bundle compliance. AlgoDx delivers actionable insights directly at the point of care through instant notifications to healthcare professionals, reducing diagnostic delays and improving patient outcomes while minimizing documentation burden. The solution supports seamless EHR integration, predictive analytics for early sepsis detection, and automatic clinical guideline compliance—helping hospitals optimize both clinical results and financial performance in critical care environments.

Harvard MedTech is a Las Vegas-based digital therapeutics company specializing in virtual reality-based treatment for trauma-related conditions and chronic pain management. The company's primary offering, Vx Therapy®, is a prescribed, at-home VR platform that combines immersive virtual reality experiences with psychosocial support, digital engagement tools, and behavioral health interventions. Vx Therapy is clinically designed to address PTSD, anxiety, depression, chronic pain, and sleep disorders—particularly for patients in workers' compensation programs seeking non-invasive alternatives to surgery and opioid-based medication. With over a decade of research and more than 4,500 prescribed patients, Harvard MedTech reports 96% physician and patient satisfaction rates alongside documented improvements in symptom reduction and lower overall treatment costs. The platform represents a convergence of evidence-based behavioral health integration with digital therapeutics, positioning VR as a legitimate clinical intervention within the telehealth ecosystem.

Amalgam Rx is a regulated digital health company specializing in Software as a Medical Device (SaMD) development. Founded in 2016 and based in Wilmington, Delaware, the company develops AI-powered, modular SaaS platforms that integrate seamlessly with electronic health records (EHR) to enhance clinical decision-making across chronic care ecosystems. The company's Medical-Grade AI™ technology supports patient identification for clinical trials, clinical decision support, digital therapeutics (DTx), caregiver engagement, and wearable device integration. Amalgam Rx's platform has facilitated over 70 million clinical decisions and currently supports nearly 10 million patients across four continents with regulatory clearance. The company partners with life sciences organizations, health plans, and healthcare providers to deliver point-of-care solutions including care guidelines, financial assistance programs, and companion products. With demonstrated FDA expertise and Manufacturer of Record (MOR) designation, Amalgam Rx emphasizes regulatory compliance, quality management systems, and global scalability across multiple markets.

Proteintech Group is a biotechnology company specializing in high-quality antibodies and protein research reagents for life sciences and pharmaceutical research. Founded in 2001 by scientists and headquartered in Rosemont, Illinois, the company manufactures a comprehensive catalog of antibodies, immunoassays, recombinant proteins, and nanobody-based reagents. Proteintech offers antibodies against 12,000+ human targets, 100+ sandwich ELISA kits, 4,000+ recombinant fusion proteins, and cGMP-grade cytokines and growth factors. Products include primary and secondary antibodies (monoclonal, polyclonal, and recombinant), conjugated antibodies for immunofluorescence and flow cytometry, immunohistochemistry kits, and magnetic cell separation kits. The company emphasizes in-house manufacturing, reproducibility, and a "scientists for scientists" approach, with products cited in over 20,000 peer-reviewed publications. Custom antibody services, polyclonal antibody production, and GMP-grade proteins support drug development and cell/gene therapy applications. Recently launched Able AI—a product recommendation tool—to accelerate scientific discovery.

Whiterabbit.ai is a healthcare AI company specializing in breast cancer screening and early detection solutions. Founded in 2017, the company develops FDA-cleared AI software integrated with mammography imaging to improve clinical outcomes, patient experience, and operational efficiency across the care continuum. WRDensity automates breast density assessment, WRRisk provides clinical decision support for cancer risk evaluation, and the ACT service optimizes patient outreach and screening compliance. With over 2 million patients served, 30+ AI scientists and healthcare professionals, and partnerships with leading institutions including Stanford University and Washington University, Whiterabbit.ai addresses critical gaps in radiologist availability while reducing false positives and improving detection accuracy through deep learning and advanced image processing technologies.

Neuro-Innovations LLC is a Chicago-based healthcare data science and informatics firm specializing in advancing medical device development and surgical outcomes optimization. The company bridges complex data analytics with actionable clinical insight through three core service areas: (1) medical device improvement using data analytics and finite element analysis; (2) surgical outcomes benchmarking and prediction leveraging local, regional, and national datasets; and (3) development of predictive algorithms and insurance models for healthcare treatments and interventions. Neuro-Innovations combines expertise in data science, informatics, and clinical surgical outcomes to support healthcare providers, device manufacturers, and payers in improving patient care quality, cost efficiency, and treatment outcomes.

Physician Software Systems develops a SaaS-based clinical decision support platform for precision dosing of medications with narrow therapeutic indices, with initial focus on erythropoietic stimulating agent (ESA) management for hemodialysis patients. The proprietary, Mayo Clinic-derived platform leverages patented algorithms and physiological modeling to deliver individualized dosing recommendations, reducing hemoglobin variability, minimizing drug costs, and improving patient outcomes. The system integrates seamlessly with existing electronic medical records (EMRs) to streamline clinician workflows, reduce manual calculation burden, and provide system-wide visibility across large patient populations. PhySoft's evidence-based approach is particularly valuable for tough-to-titrate drugs requiring frequent dose adjustments and complex clinical evaluation.

Swan Valley Medical is a medical technology and data analytics company specializing in suprapubic bladder management solutions for hospitals. The company develops T-SPeC®, a proprietary medical instrument technology for catheterization procedures, combined with Swan Informatics™—a predictive analytics platform that quantifies clinical outcomes and cost savings. Leveraging evidence-based data from over 500 clinical studies, Swan Valley enables hospitals to reduce preventable complications, mortalities, and associated costs. The solution targets fundamental improvements in urinary retention management and infection control, addressing clinical practices that have remained largely unchanged for over a century. Designed for hospital procurement, risk management, and materials management departments, Swan Valley's B2B offering combines device innovation with hospital-grade informatics to improve patient outcomes and operational efficiency.

AnthroTronix is an award-winning research and development company specializing in human-centered technology and human-computer interface design. The company develops innovative software and hardware solutions for mobile computing platforms and robotic systems, with particular expertise in cognitive assessment, therapeutic interventions, surgical simulation, and military training applications. AnthroTronix provides advanced product development and R&D services to commercial and governmental sector clients, with deep capabilities in multimodal interfaces, haptic feedback devices, human factors evaluation, and experimental design. The company's interdisciplinary team of engineers, scientists, and designers focuses on optimizing human-technology interaction across health, communication, education, and defense domains.

Rahm Sensor Development specializes in non-contact vital signs monitoring using patented Doppler Radar and FMCW (Frequency Modulated Continuous Wave) sensing technology. The company's AI-enabled sensor platform captures real-time health data including respiratory rate, heart rate, and blood flow without requiring skin contact, reducing patient discomfort and cross-contamination risk. Core applications span neonatal intensive care, memory care facilities, and correctional facilities. The Guardian solution integrates machine learning for outcome prediction and pattern anomaly detection, enabling healthcare professionals and facility staff to make informed clinical and safety decisions. Rahm's technology emphasizes non-invasive monitoring, rapid alert generation, and reduced caregiver burden across acute and specialty care settings.

HealthArc is a comprehensive digital health platform specializing in remote patient monitoring (RPM), chronic care management (CCM), and care coordination software for healthcare providers. The platform integrates with over 40 compatible medical devices (blood pressure monitors, glucometers, pulse oximeters, weight scales, spirometers, continuous glucose monitors, thermometers, and medication adherence trackers) to enable real-time vital sign monitoring and patient data collection. HealthArc's unified care platform features AI-driven clinical pathways, automated workflow management, and intelligent patient communication via SMS and phone escalation. The software supports multiple CMS-compliant care programs including Remote Patient Monitoring, Chronic Care Management, Principal Care Management, Remote Therapeutic Monitoring, Transitional Care Management, Medication Therapy Management, Behavioral Health Integration, and Advanced Primary Care Management. The platform automates billing documentation and claims submission across these programs, integrates with existing EHR systems, and includes specialized clinical support services with enrollment specialists, RNs, LPNs, and medical assistants. HealthArc serves hospitals, primary care practices, virtual care delivery companies, and managed healthcare organizations, with current deployment across 40+ states serving 750+ providers and 65,000+ patients. The company prioritizes HIPAA compliance, SOC2 certification, and FDA-approved device integration.

Creyos is a Toronto-based digital health platform specializing in scientifically validated cognitive and behavioral health assessments. Built on 30+ years of neuroscience research and supported by 400+ peer-reviewed studies, the platform delivers 12 validated cognitive tasks that assess short-term memory, reasoning, attention, verbal ability, decision-making capacity, and executive function. Designed for seamless in-clinic or remote deployment without specialized equipment, Creyos generates real-time reports supporting early detection and monitoring of cognitive impairment, mild cognitive impairment (MCI), dementia, ADHD, Parkinson's disease, traumatic brain injury, and behavioral health conditions. The platform integrates with existing clinical workflows, supports both fee-for-service and value-based care models, and includes digital questionnaires for behavioral evaluation. Features include audio and visual guidance, multi-lingual support, and HIPAA-compliant data security. Used by 10,000+ healthcare providers including primary care, neurology, psychiatry, and specialized rehabilitation centers.

SeniorLife.AI is an AI-powered wellness platform designed for senior living operators, longevity clinics, concierge medicine practices, and rehabilitation providers. The platform utilizes vision-based artificial intelligence and passive monitoring technologies to predict mobility and cognitive decline risk months to years in advance. Core capabilities include Risk Insights (AI-trained on 4M mobility records and 2.5M cognitive decline cases), Mobility Metrics Tracker (FDA Class II SaMD—30 gait and balance metrics from 30-second smartphone video), Gaze Metrics Analysis (5-minute iPad eye movement test for early cognitive impairment detection), and Dynamic Care Plan (role-specific action synthesis integrated with EHR systems via SMART on FHIR). The platform also features passive 24/7 room radar monitoring and on-demand vitals scanning. Trained on Mayo Clinic records, SeniorLife.AI integrates seamlessly into existing clinical workflows and can be white-labeled via API. The solution targets fall prevention, functional performance tracking, and objective evidence for discharge planning and CMS reimbursement justification in post-acute care settings.

Neuromersive Inc (operating as Neuro Rehab VR) is an FDA-registered, HIPAA-compliant virtual reality healthcare technology company specializing in AI-powered immersive XR therapy systems for neurological rehabilitation. Founded in 2017 and based in Fort Worth, Texas, the company develops the Smart Therapy™ Complete Solution—an integrated platform combining VR headsets, motion controllers, clinician tablets, and comprehensive software libraries for evidence-based therapy exercises. The system addresses upper and lower extremity rehabilitation, cognitive therapy, pain management, and anxiety relief through engaging 3D immersive applications. The platform includes an AI-powered analytics portal for real-time progress tracking, automated therapy documentation, and patient management. Clinical evidence demonstrates 92% improvement in patient motivation, 85% pain reduction, 50% reduction in documentation time, and 35% increase in billing ROI. Trusted by major healthcare systems including Cedars-Sinai, MD Anderson, Kaiser Permanente, Penn Medicine, Ascension, and the U.S. Veterans Affairs, Neuro Rehab VR has delivered therapy to over 350 patients across thousands of sessions. The solution serves hospitals, outpatient clinics, skilled nursing facilities, and government healthcare providers.

DASI Simulations develops FDA-cleared AI-powered cardiac simulation software that provides interventional cardiologists and cardiac surgeons with patient-specific predictive modeling for structural heart procedures. The platform uses advanced computational analysis of cardiac imaging (CT, echocardiography) to generate personalized 3D reconstructions and risk assessments for transcatheter aortic valve replacement (TAVR) and other valve interventions. Key capabilities include prediction of coronary obstruction risk, leaflet thickening/thrombosis formation, and procedure optimization. The DASI app enables clinicians to visualize treatment options and optimize planning before surgery, enhancing patient safety and procedural outcomes. Trusted by major health systems including Cleveland Clinic, Piedmont Healthcare, Wexner Medical Center, and Baylor Scott & White, DASI Simulations' technology integrates with clinical workflows to support heart teams in pre-operative decision-making and risk stratification.

Medical Decision Network (MDN) provides comprehensive healthcare software solutions focused on improving critical care quality and outcomes. The company specializes in ICU performance analytics, glycemic control management, and predictive severity modeling. MDN's flagship products include GlucoStabilizer®, an FDA-cleared IV insulin dosing system that automates glucose management and reduces hypoglycemia risk in hospitalized patients, and MDN PHOENIX, a critical care software platform featuring ACUITY 2019 predictive modeling for severity-adjusted outcome measurement. ACUITY 2019 delivers fully automated severity scoring with observed/expected calculations for length of stay, hospital mortality, and mechanical ventilation duration predictions—eliminating manual data collection while improving upon legacy APACHE models. ICUTracker® provides outcomes reporting and ICU performance benchmarking capabilities. These solutions enable hospitals to optimize clinical workflows, reduce glycemic variability complications, and drive data-driven process improvements across critical care units.

REEV is a medical robotics company specializing in personalized mobility solutions for individuals with neurological gait disorders, including stroke survivors, multiple sclerosis, and paraplegia patients. The company offers an integrated two-product platform: REEV SENSE, an AI-powered wearable gait analysis system that captures real-time kinematic data via dual sensors, and DREEVEN, a motorized knee-ankle-foot orthosis (KAFO) that provides personalized robotic assistance based on patient-specific gait signatures. The system enables certified orthotists and rehabilitation clinics to perform rapid gait calibration, monitor patient progression through mobile analytics, and deliver customized motor control assistance in outpatient and clinical settings. REEV's technology integrates electro-hydraulic actuation with machine learning algorithms to adapt orthotic support dynamically to each patient's walking pattern, improving functional mobility and independence.

Diagenode, a Hologic subsidiary since 2021, is a global leader in epigenomics research solutions and sample preparation products for next-generation sequencing (NGS), proteomics, and molecular diagnostics. Based in Seraing, Belgium, with ~150 employees, the company develops innovative instruments, reagents, and comprehensive assay services for epigenetics research and biomarker discovery. Core product lines include DNA shearing systems (Bioruptor®, Megaruptor®, One®), automation platforms (IP-Star®), antibodies, NGS library preparation kits, and specialized reagents for chromatin studies, DNA methylation analysis, CRISPR/Cas9 applications, and ATAC-seq workflows. Diagenode also delivers epigenomics profiling services, bioinformatics support, and over 30 CE-marked real-time PCR diagnostic assays. The company's focus is supporting academic and clinical laboratories in advanced epigenetic research and molecular diagnostics.

MRS Health, Inc. is an AI-enabled population health management company specializing in musculoskeletal disorder (MSD) prevention, diagnosis, and treatment. The organization delivers an integrated care program combining predictive analytics, functional restoration therapy, and connected home rehabilitation devices. MRS Health uses proprietary algorithms and supervised learning AI to identify at-risk populations from medical and pharmacy claims data, enabling early intervention and cost mitigation. The company operates center-based functional restoration programs staffed by physicians, physical therapists, exercise physiologists, and health coaches, utilizing biomechanically optimized equipment and IT platforms. For distributed workforces, MRS Health provides telehealth-enabled connected strengthening devices for spine, back, and neck rehabilitation—devices designed for home use that deliver clinically proven outcomes. The company targets leading healthcare cost drivers including musculoskeletal conditions, opioid use disorder, mental health, diabetes, and durable medical equipment expenses, with demonstrated ROI exceeding 3.5:1 for employer-sponsored health plans.

Conversio Health is a healthcare services and pharmacy provider specializing in comprehensive management of chronic respiratory conditions, particularly COPD and asthma. Founded in 2012 and based in San Luis Obispo, California, the company serves patients, healthcare providers, and health plans across more than 40 states. The company operates a high-touch pharmacy model emphasizing home delivery, personalized patient education, and integrated clinical support. Conversio Health's integrated platform includes custom nebulizer medications optimized for drug delivery and lung penetration, smart portable Bluetooth-enabled devices that capture medication adherence in real time, and a pocket-sized portable nebulizer for simplified medication administration. The company provides the Inspire™ virtual pulmonary rehabilitation program—a comprehensive COPD self-management solution featuring exercise videos, health education, and smoking cessation content. Central to its offering is an AI-driven predictive analytics engine that monitors patient data in real time, identifies high-risk patients, and delivers actionable alerts to clinical teams via the Conversio Connect app. Clinical support includes pharmacists, respiratory therapists, and health coaches providing high-touch pharmacotherapy management and patient education. The program demonstrates strong clinical outcomes: 81% improvement in medication adherence, 27% reduction in ED visits and hospitalizations, 31% reduction in total medical costs, and 94% patient satisfaction.

MyndTec Inc. is a medical technology company specializing in neurotechnology products and AI-powered software solutions for treating neurological disorders, chronic pain, and central nervous system injuries including stroke and spinal cord injuries. The company's primary offering, MyndMove™, is a non-invasive neuromodulation therapy that uses electrical stimulation to trigger neuroplasticity, enabling patients with paralysis to regain movement and function. MyndLink™, an AI-powered clinical decision support platform, predicts treatment outcomes, optimizes protocols, and automates clinical workflows to improve patient recovery while reducing healthcare costs. MyndTec integrates advanced machine learning and predictive analytics to address critical gaps in neurological care, particularly the 60-70% of stroke survivors experiencing persistent upper limb impairment and the 30% failure rate of spinal cord stimulator procedures. The company is also developing regenerative therapies utilizing neural stem cells for brain tissue repair. Both products are authorized in the U.S. and Canada, targeting rehabilitation facilities and neurological care centers seeking evidence-based, outcome-optimized treatment solutions.

Mirada Medical is a UK-based medical imaging software company founded in 2000, with deep roots in Oxford University research (originating from 1998). Headquartered in Oxford, the company specializes in AI-driven, vendor-neutral software solutions designed to accelerate cancer care through precision imaging. The company's portfolio targets three primary clinical domains: radiation oncology, diagnostic imaging, and interventional radiology. Key products include Mirada RTx, which automates radiation therapy planning workflows and enhances treatment planning confidence, and Mirada XD, an advanced image registration and visualization platform for enterprise diagnostic imaging. Mirada's solutions incorporate deep learning and AI-based quantification tools to support clinician productivity, multi-timepoint follow-up analysis, and automated reporting (particularly for PET/CT and PET/MR imaging). The company maintains strong partnerships with major medical device manufacturers including Canon and Boston Scientific, and collaborates with clinical facilities on research-driven innovation to improve patient outcomes and address imaging-related clinical challenges.

Etiometry, Inc. is a Boston-based medical technology company specializing in AI-driven clinical decision-support software for intensive care units (ICUs). The Etiometry Platform (T3 Platform) aggregates real-time patient data from bedside monitors, peripheral devices, and EHR systems into a unified dashboard powered by Bayesian models and proprietary AI algorithms. The platform computes personalized risk indices to enable proactive care management in both pediatric and adult critical care settings. Core features include data aggregation and visualization, risk analytics for hemodynamic and respiratory management, automated clinical pathway workflows aligned with hospital protocols, and quality improvement analytics. The platform has received 11 FDA 510(k) clearances and CE marking, and has been deployed across 150+ clinical studies leveraging 150+ million hours of de-identified patient data. Clinical evidence demonstrates up to 36% reduction in length of stay, 41% decrease in ICU readmissions, 30% reduction in mechanical ventilation time, and 29% shorter vasoactive infusion duration. Trusted by leading academic medical centers and top-ranked children's hospitals across North America, Europe, and Asia.